



## Mascha Pervan

Germany

With great delight I saw the ENYGO Executive Group Elections as I aim to expand my contribution to the ENYGO community and their mission.

Clinically, I work as a consultant and fellow of Gynaecologic Oncology at Universityhospital Munster,

Germany within an expanding certified cancer centre, combining surgical, medical, and academic responsibilities. I continuously expanded my interest in research collaborations, training opportunities and exchange of knowledge as I experienced the immense value of scientific progress as well as improved clinical and surgical skills for my patients.

I value the scientific approach and immediate implementation of new findings and at the same time experienced the need for infrastructure to provide the best care.

Connecting with colleagues at ESGO courses and meetings I realised most face similar challenges anywhere, but also little differences might inspire meaningful improvement. I strongly believe that only collaboration can truly advance our field (and actually anything).

So I admire the foundation of ESGO and ENYGO to unite expertise and drive progress collectively for research, education, advocacy and inclusion. Building a research group and collaborations at our expanding center, combined with my experience in coordinating multidisciplinary cancer care, implementing change and teaching residents demonstrates my strategic thinking and dedication to collaborative leadership.

I am deeply committed to strengthening visibility, community and impact of young gynaecologic oncologists across Europe. With enthusiasm, inspiration, and a strong commitment to our shared mission, I would be honoured to serve the ENYGO community within the Executive Group.

## **Curriculum vitae**

On my first day of gynaecology and obstetrics training I was placed in the oncologic systemic therapy's clinic instead of the delivery ward which was a surprise to me. I spend the next 10 months applying targeted and chemotherapies to breast and gynaecological cancer patients, following their journey, and personal experiences I had the honour to learn so much not only clinically and scientifically implementing advances immediately upon publication but also the personal challenges, different approaches to a disease and life and left the rotation feeling blessed for many shared experiences.

Previously my interest in oncology has already been sparked working on my thesis about triple-negative breast cancer but working with patients in all stages of their cancers for 10 months consecutively increased my enthusiasm significantly.

In collaboration with the Institute for Pathology of the University I investigated Immuncheckpointmarkers in tissue of triple-negative breast cancer, which has widely recognised as shown through invited speaker engagements and prizes. My MD thesis earned me a magna cum laude distinction, laid the groundwork to my scientific efforts and sparked my profound enthusiasm for research.

Throughout my entire speciality training at the Universityhospital Lubeck, Germany I was Deputy- and Principal Investigator for numerous international clinical trials, consistently managing complex research projects effectively and with great diligence. I enhanced the workflow and collaboration of the team. This was most proficiently shown in my role as German Lead Principal Investigator of the ITT "CaEP", a Phase-II Trial on Calcium Electroporation in Cutaneous Metastases.

In an international cooperation with Danish oncologists, we secured EU funds, developed the study protocol and I subsequently managed all legal and administrative aspects successfully for the German study site and carried out the trial at our centre. This resulted in a participation at the ESMO congress 2022 and publication of results.

After completion and early sub-specialization training in Gynaecologic oncology I transferred to Sanaklinik Offenbach, a teaching hospital of the University Frankfurt, where I worked as a consultant and continued my training. I was appointed Head of Clinical Trials Office and happily took over Operational Lead of the certified cancer centre, where 4 months after my appointment I lead the successfully Re-Audit together with an enthusiastic team.

One year ago, my former consultant and mentor asked me to join him at Universityhospital Munster where he was appointed chair. Here I work as a consultant and continue my gynaecologic oncology training while with a brilliant team we are transforming the department into a centre of excellence in gynaecological oncology. Clinically, my work spans the full spectrum of gynaecologic oncology, I participate in complex oncologic procedures, including cytoreductive surgery and minimally invasive

techniques. I recently received the German Robotic Surgery Fellowship in Gynaecology, where extra dry and wet lab days are part of a structured curriculum to advance robotic surgery skills.

I have contributed actively to the optimisation of multidisciplinary care pathways. I assumed the role of Operational Lead of the certified Gynaecologic Cancer Centre, here I manage the certification processes, quality metrics, ERAS implementation, patient information frameworks, and the introduction of structured patient support resources such as information and survivorship materials, and local advocacy contacts.

I am a current Editorial Fellow of the International Journal of Gynecological Cancer, gaining in-depth experience in manuscript review, editorial decision-making, social media dissemination, and scholarly communication and love my engagement in the ENYGO Social Media Committee, contributing to increase engagement, outreach, and network visibility. This work has strengthened my understanding of member needs, digital communication strategies, and the value of fostering a connected, enthusiastic community of young oncologists.

# Dr. Mascha Pervan, MD

## List of Publications:

Hartwig-Cywnar, S; Proppe, L; Eltrop, S; Witteler, R; Hanker, LC; **Pervan, M.** Upstaging after positive peritoneal biopsies in ovarian tumours – a real-world 10-year tertiary cancer centre analysis. Submitted abstract for ESGO Congress 2026

**Pervan, M.**; Proppe, L; Princk, H; Berg, N; Hanker, L. Finding The Rare Among The Unusual: A Primary Papillary Thyroid Carcinoma In An Ovarian Tumour. Accepted abstract for the IGCS Annual Meeting in Capetown in November 2025 with publication in Int J Gynecol Cancer.

Princk, M. H.; **Pervan, M.**; Riedl, J. „*Adverse Events in Immunotherapy*“ Nebenwirkungsmanagement unter Immuntherapie. Urol. 2025, 64 (3), 281–287. <https://doi.org/10.1007/s00120-024-02517-x>.

**Pervan, M.**; Princk, H.; Meneder, S.; Banys-Paluchowski, M.; Fehm, T.; Ruckhäberle, E.; Hanker, L.; Fitzgerald, S.; Rody, A.; Krawczyk, N. Seltene Malignome der Brust. Gynäkol. 2024, 57 (1), 42–48. <https://doi.org/10.1007/s00129-023-05176-9>.

Vissing, M.; **Pervan, M.**; Ploen, J.; Schnefeldt, M.; Rafaelsen, S. R.; Jensen, L. H.; Rody, A.; Gehl, J. Calcium Electroporation in Cutaneous Metastases – A Non-randomised Phase II Multicentre Clinical Trial. Eur. J. Cancer. 2023. <https://doi.org/10.1016/j.ejso.2023.04.024>

Princk, M. H.; **Pervan, M.**; Riedl, J. „*Adverse Events in Immunotherapy*“ Nebenwirkungsmanagement unter Immuntherapie. Gynäkol. 2023. <https://doi.org/10.1007/s00129-023-05067-z>.

Humbeck, C.; Jonassen, S.; Bringewatt, A.; **Pervan, M.**; Rody, A.; Bossung, V. Timing of Antenatal Steroid Administration for Imminent Preterm Birth: Results of a Prospective Observational Study in Germany. Arch. Gynecol. Obstet. 2022. <https://doi.org/10.1007/s00404-022-06724-9>.

Princk, M. H.; **Pervan, M.**; Riedl, J. „*Managing Adverse Events in Immunotherapy*“ Immuntherapie: Nebenwirkungen managen. ProCare 2024, <https://doi.org/10.1007/s00735-024-1795-4>.

Princk, M. H.; **Pervan, M.**; Riedl, J. „*Managing Adverse Events in Immunotherapy*“ Immuntherapie: Nebenwirkungen managen. Pflegezeitschrift 2024, 77 (1), 30–33. <https://doi.org/10.1007/s41906-023-2230-3>.

**Pervan, M.**; Gembicki, M.; Princk, H.; Rody, A.; Hunker, L.; Hemptenmacher, F.; Banys-Paluchowski, M. Primary Ovarian Leiomyoma: A Rare Ovarian Tumour. Arch. Gynecol. Obstet. 2022. <https://doi.org/10.1007/s00404-022-06842-4>.

Vissing, M.; Ploen, J.; **Pervan, M.**; Vestergaard, K.; Schnefeldt, M.; Frandsen, S. K.; Rafaelsen, S. R.; Lindhardt, C. L.; Jensen, L. H.; Rody, A.; Gehl, J. Study Protocol Designed to Investigate Tumour Response to Calcium Electroporation in Cancers Affecting the Skin: A Non-Randomised Phase II Clinical Trial. BMJ Open 2021, 11 (6), e046779. <https://doi.org/10.1136/bmjopen-2020-046779>.

**Pervan, M.**; Bräutigam, K.; Thorns, C.; Rody, A.; Liedtke, C. Immune Checkpoint Marker Expression and Clinicopathological Factors in Primary TNBC. J. Clin. Oncol. 2018, 36 (15\_suppl), e13119–e13119. [https://doi.org/10.1200/JCO.2018.36.15\\_suppl.e13119](https://doi.org/10.1200/JCO.2018.36.15_suppl.e13119).

Bräutigam, K.; Mitzlaff, K.; Uebel, L.; Köster, F.; Polack, S.; **Pervan, M.**; Steinert, G.; Rody, A.; Liedtke, C. Subtypes of Triple-Negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate. Anticancer Res. 2016, 36 (6), 2759–2766. PMID: [27272786](https://doi.org/10.21873/anticanres.27272786).

## Dr. Mascha Pervan, MD

**Pervan, M.**; Fick, F.; Princk, H.; Weichert, J. „*Huge Cystadenoma of the Ovary – a „heavy“ case“* Riesiges Zystadenom des Ovars – ein „schwerer“ Fall. Geburtshilfe Frauenheilkd 2022; 82(10): e140. <https://doi.org/10.1055/s-0042-1756992>.

**Pervan, M.**; Krawczyk, N.; Hunker, L.; Bündgen, N.; Rody, A.; Banys-Paluchowski, M. „*Significant Increase in Overall Survival with Sacituzumab-Govitecan for Metastatic Breast Cancer*“ Deutliche Verbesserung des Gesamtüberlebens durch Sacituzumab-Govitecan beim metastasierten tripelnegativen Mammakarzinom. Onkol. 2021, 27 (11), 1131–1136. <https://doi.org/10.1007/s00761-021-01034-2>.

**Pervan, M.**; Bündgen, N. „*Case: 45 yo with Galactorrhea*“ 45/w mit Galaktorrhö. Gynäkol. 2021, 54 (1), 11–15. <https://doi.org/10.1007/s00129-021-04770-z>.

**Pervan, M.**; Princk, H.; Hunker, L.; Rody, A.; Bündgen, N.; Banys-Paluchowski, M. „*Impressive Increase in Survival for Metastatic HER2-low-Breast Cancer – Establishment of a Novel Subgroup?*“ Eindrückliche Verbesserung des Überlebens beim metastasierten HER2-low-Mammakarzinom – Etablierung einer neuen Subgruppe? Onkol. 2022. <https://doi.org/10.1007/s00761-022-01276-8>.

### Invited Speaker (Selection):

“Immunohistochemical Expression of Immuncheckpointmarkers - Analysis of Clinico-pathological Parameters in Triple-Negative Breast Cancer“ at **62th Congress of the German Society for Gynaecology and Obstetrics (DGGG)** in Berlin, Germany, 31. Oct - 03. Nov 2018

“Immunohistochemical Expression of Immuncheckpointmarkers - Analysis of Clinico-pathological Parameters in Triple-Negative Breast Cancer“ at **XXVth Academic Meeting of Germanspeaking University Professors** 2017 in Mannheim and Heidelberg, Germany, 5.-6.Oct. 2017

### Prize for Best Abstract:

Beacon of the North of the Northgerman Society for Gynaecology and Obstetrics (NGGG) 2017: „Immunohistochemical Expression of Immuncheckpointmarkers - Analysis of Clinico-pathological Parameters in Triple-Negative Breast Cancer“

### Posters (selection):

„1295TiP - Investigation of Calcium Electroporation (CaEP) Therapy in Malignant Cutaneous and Subcutaneous Tumours - a Non-Randomized Phase II Clinical Trial of a Novel Palliative Therapy“ **European Society for Medical Oncology (ESMO) Congress 2022**, 9. – 13. Sept 2022 in Paris, France

„Genomic profiling for precision-based medicine in breast cancer patients – A single centre experience from the University Hospital Schleswig-Holstein“ **64th Congress of the German Society for Gynaecology and Obstetrics (DGGG)**, 12.– 15. Oct 2020 in Munich, Germany

“Optimal Duration of Bevacizumab in Combination with Carboplatin and Paclitaxel for Primary Epithelial Ovarian-, Fallopian Tube or Peritoneal cancer – a Randomized Multicenter Open-Label Phase-3- ENGOT/GCIG-Study of the AGO Workinggroup, GINECO and NSGO (AGO-OVAR 17/BOOSR, GINECO OV118, ENGOT Ov-15, NCT01462890)“ „Optimale Therapiedauer von Bevacizumab (BEV) in Kombination mit Carboplatin und Paclitaxel beim primären epithelialen Ovarial- (EOC), Tuben- (FTC) oder Peritonealkarzinom (PPC) – eine randomisierte Multicenter Open-label Phase-3-ENGOT/GCIG-Studie der AGO-Studiengruppe, GINECO und NSGO (AGO-OVAR 17/BOOSR, GINECO OV118, ENGOT

## Dr. Mascha Pervan, MD

Ov-15, NCT01462890)“ **134th Meeting of Northgerman Society for Gynaecology and Obstetrics (NGGG)**, 22.-23. Oct 2021 in Luebeck, Germany

“*Correlation of Immunohistochemical Expression of TRK and Clinico-pathological Parameters in Triple-Negative Breast Cancer*“ „Untersuchungen zu Korrelationen von immunhistochemischer TRK-Expression und klinisch-pathologischen Parametern beim tripel-negativen Mammakarzinom“ **63th Congress of the German Society for Gynaecology and Obstetrics (DGGG)**, 07.– 10. Oct 2020 in Munich, Germany/Online

„*Immunohistochemical Expression of Immuncheckpointmarkers - Analysis of Clinico-pathological Parameters in Triple-Negative Breast Cancer*“ „Untersuchungen zu immunhistochemischer Expression von Immuncheckpoint-Markern und klinisch-pathologischen Parametern beim Tripel-negativen Mammakarzinom“ **132th Meeting of Northgerman Society for Gynaecology and Obstetrics (NGGG)**, 08.-09. Sept 2017 in Hannover, Germany